ViraChem.ResearchWe connect pharmaceutical companies and biotech labs with licensed peptide CDMOs across Europe — handling sourcing, due diligence, and regulatory alignment so your team can focus on the science.
Vendor qualification frameworks, CoA interpretation, and dual-source strategies for high-purity peptide APIs across the EU.
EMA guidelines, manufacturing compliance, ICH Q7, and GDPR implications for synthetic peptide drug substance development.
Study design, bioanalytical method validation, and stability programmes for peptide NCEs entering first-in-human trials.
Capability benchmarks, technology assessments, and strategic sourcing frameworks across European peptide CDMOs.
Research Repository
Understanding ICH S7A, Q1A(R2), and EMA Bioanalytical Method Validation requirements for peptide stability studies supporting EU regulatory packages.
A comprehensive review of EMA reflection papers and guideline updates affecting identity, purity, and impurity control for synthetic peptide APIs in EU regulatory submissions.
Key evaluation dimensions for selecting a European peptide CDMO: synthesis technology capabilities, quality systems maturity, regulatory track record, and commercial terms.
A systematic framework for qualifying peptide CDMOs for first-in-human studies, covering vendor audit criteria, Certificate of Analysis requirements, and ICH Q7-aligned quality agreements.
ViraChem Platform
This is the research blog. The full B2B sourcing and CDMO intermediary platform — with supplier listings, RFQ tools, and due diligence frameworks — is available at virachemical.com.